Delivery Order SPE2DB20D9329-SPE2DB25FZK78
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a firm fixed-price delivery order valued at $9,906.30 by the Defense Logistics Agency (DLA) for the supply of EYLEA HD 8 mg/0.07 ml vials. The contract, issued on August 1, 2025, with an ultimate completion date of August 22, 2025, carries no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $15,850.16 on July 21, 2025, for the supply of EYLEA HD 8 mg/0.07 ml vials. This delivery order, with an ultimate completion date of August 11, 2025, was issued without a set-aside designation and will be performed at the awardee's Park Ridge location. The order is funded through the Defense Logistics Agency's Medical...
- The Defense Logistics Agency awarded DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, a firm fixed-price delivery order valued at $24,446.00 for EYLEA 2 mg/0.05 mL syringes. The award, issued on July 31, 2025, with an ultimate completion date of August 21, 2025, does not utilize a set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the...
- The Defense Logistics Agency issued a delivery order valued at $7,925.08 to DMS Pharmaceutical Group Inc. for EYLEA HD 8 mg/0.07 ml vials on July 25, 2025, with an ultimate completion date of August 15, 2025. EYLEA is a prescription pharmaceutical product used in the treatment of retinal diseases. This delivery order was issued under a firm fixed-price contract type with no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $7,925.08 on July 29, 2025, for the supply of EYLEA HD 8 mg/0.07 mL vials. The contract is a firm fixed-price delivery order with an ultimate completion date of August 19, 2025, and was issued without a set-aside designation. This award is funded by the Department of Defense through its Medical Supply Chain function and represents a...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $29.3 thousand by the Defense Logistics Agency's Medical Supply Chain on July 28, 2025. The contract covers the delivery of EYLEA 2 mg/0.05 ml syringes to support federal healthcare requirements, with an ultimate completion date of August 18, 2025. This delivery order was issued without a set-aside designation and is...
- The Defense Logistics Agency awarded a $3,770.31 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for EYLEA 2 mg/0.05 mL vials on August 7, 2025, with an ultimate completion date of August 28, 2025. EYLEA is a prescription anti-vascular endothelial growth factor medication used to treat age-related macular degeneration and other retinal conditions. The contract was performed in Park Ridge, Illinois, where DMS Pharmaceutical Group maintains its headquarters. No set-aside...
- This is a firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $7,540.68 contract is for the delivery of EYLEA 2 MG/0.05 ML VIAL 0.05ML, with a period of performance through July 28, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with DLA under the SPE2DB program, which enables the agency to issue delivery...
- The U.S. Defense Logistics Agency Troop Support Medical awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $40,717.88 contract is for the delivery of EYLEA 2 MG/0.05 ML VIAL 0.05ML, a prescription drug product, with a completion date of March 25, 2024. This delivery order is issued under DMS Pharmaceutical Group's broader indefinite delivery contract 4600082013 with the...
- The U.S. Department of Defense's Defense Logistics Agency awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $15,761.76 contract is for the delivery of EYLEA 2 MG/0.05 ML VIAL 0.05ML, a medication, with a period of performance through September 23, 2024. This delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) that DMS Pharmaceutical Group...
- SPE2DB20D9329Indefinite Delivery Contract
- SPE2DB20D9329-SPE2DB25FZK78Delivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $15,081.24 by the Defense Logistics Agency on August 11, 2025, for the supply of EYLEA 2 mg/0.05 ml vials. The contract utilizes firm fixed-price pricing and carries an ultimate completion date of September 2, 2025. No set-aside designation was applied to this award. This delivery order is issued under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, which is valued at $499,999,999 and remains valid through November 2026. EYLEA is a biologic medication commonly used in ophthalmology for treating retinal conditions. The delivery order reflects DMS Pharmaceutical Group's established role as a critical supplier within the federal pharmaceutical supply chain, providing specialized pharmaceutical products to Department of Defense healthcare facilities. The company's consistent success in securing delivery orders for high-value specialty medications, including biologics and branded pharmaceutical products, underscores its strategic importance to the DLA's medical supply operations supporting military health systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.1k | 8/11/25 |